Overcoming Resistance to PARP Inhibitors in BRCA-Mutated Cancers: Mechanisms and Therapeutic Strategies
The tumor suppressor genes BRCA1 and BRCA2 are essential for homologous recombination (HR) repair. Mutations in BRCA1/2 compromise HR repair efficacy, resulting in heightened susceptibility of tumor cells to poly (ADP-ribose) polymerase inhibitors (PARPi) via synthetic lethality. To date, several PARPi have been approv...